Gennex Lab.

{
  "main_header": {
    "sid": 930938,
    "name": "Gennex Lab.",
    "stock_name": "Gennex Lab.",
    "full_name": "Gennex Laboratories Ltd",
    "name_url": "stocks-analysis/gennex-lab",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "10.04",
    "chg": -0.3,
    "chgp": "-2.9%",
    "dir": -1,
    "prev_price": "10.34",
    "mcapval": "249.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531739,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE509C01026",
    "curr_date": "Jun 11, 03:30 PM",
    "curr_time": "21:32 PM",
    "last_traded_at": "Jun 11, 03:30 PM IST",
    "bse_nse_vol": "2.73 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 11, 2026",
    "traded_date_str": "2026 06 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/gennex-lab-930938-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Gennex Laboratories Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-laboratories-ltd-is-rated-hold-4046425",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GennexLaborator_mojoScore_4046425.png",
        "date": "2026-06-11 10:10:40",
        "description": "Gennex Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Are Gennex Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-gennex-laboratories-ltd-latest-results-good-or-bad-4032452",
        "imagepath": "",
        "date": "2026-06-02 19:35:43",
        "description": "Gennex Laboratories Ltd's latest financial results for the quarter ended March 2026 present a complex picture. The company achieved net sales of ₹60.96 crores, reflecting a substantial year-on-year growth of 51.15%, which marks the highest quarterly revenue in its recent history. This growth indicates robust demand for Gennex's products, particularly in the active pharmaceutical ingredients (API) and intermediates segment.\n\nHowever, this impressive top-line growth was not mirrored in profitability metrics. The operating margin, excluding other income, fell sharply to 9.66% from 23.61% in the same quarter last year, indicating significant margin compression. This decline raises concerns about the company's cost management and pricing strategies, suggesting that the growth may have come at the expense of profitability. The net profit for the quarter was reported at ₹3.74 crores, which, while showing a year-on..."
      },
      {
        "title": "Gennex Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4029412",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GennexLaborator_valuationdot_4029412.png",
        "date": "2026-06-02 08:04:15",
        "description": "Gennex Laboratories Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, driven by a notable decline in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change comes against a backdrop of mixed sector performance and a challenging market environment, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks."
      },
      {
        "title": "Gennex Laboratories Q4 FY26: Profit Surge Masks Margin Compression Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/gennex-laboratories-q4-fy26-profit-surge-masks-margin-compression-concerns-4028764",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GennexLaborator_quaterlyResult_4028764.png",
        "date": "2026-06-01 15:16:03",
        "description": "Gennex Laboratories Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharmaceutical ingredients and intermediates, reported consolidated net profit of ₹3.74 crores for Q4 FY26, marking a robust 61.21% year-on-year growth but a concerning 28.63% sequential decline. The Telangana-based company, with a market capitalisation of ₹285.00 crores, saw its stock retreat 4.42% to ₹11.25 following the results announcement, reflecting investor concerns over deteriorating operating margins despite impressive top-line expansion."
      },
      {
        "title": "Gennex Laboratories Ltd Reports Strong Quarterly Turnaround Amid Mixed Long-Term Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-ltd-reports-strong-quarterly-turnaround-amid-mixed-long-term-returns-4026587",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GennexLaborator_fintrenddot_4026587.png",
        "date": "2026-06-01 12:01:16",
        "description": "Gennex Laboratories Ltd has demonstrated a notable turnaround in its financial performance for the quarter ended March 2026, with significant growth in profitability and revenue, despite a challenging market environment and a recent downgrade in its Mojo Grade to Sell."
      },
      {
        "title": "Are Gennex Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-gennex-laboratories-ltd-latest-results-good-or-bad-4023909",
        "imagepath": "",
        "date": "2026-05-30 19:51:14",
        "description": "Gennex Laboratories Ltd's latest financial results present a mixed picture, highlighting both robust revenue growth and significant operational challenges. For the fiscal year 2025, the company reported a notable net sales increase of 59.30% year-on-year, reaching ₹137.00 crores, up from ₹86.00 crores in the previous year. This growth is supported by a strong five-year compound annual growth rate (CAGR) of 22.71%, indicating a consistent upward trend in sales.\n\nHowever, the operational metrics reveal concerning trends. The net profit for FY25 rose to ₹18.00 crores, reflecting a 38.46% increase year-on-year, but this growth lagged behind the sales expansion. The profit after tax margin contracted to 13.10% from 15.10% in FY24, suggesting deteriorating operational efficiency. Furthermore, the operating margin (excluding other income) saw a significant decline, dropping to 11.70% from 19.80%, raising questions..."
      },
      {
        "title": "Gennex Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-laboratories-ltd-is-rated-sell-4020054",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GennexLaborator_mojoScore_4020054.png",
        "date": "2026-05-29 10:10:03",
        "description": "Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing."
      },
      {
        "title": "When is the next results date for Gennex Laboratories Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-gennex-laboratories-ltd-4001748",
        "imagepath": "",
        "date": "2026-05-20 23:19:00",
        "description": "The next results date for Gennex Laboratories Ltd is scheduled for 30 May 2026...."
      },
      {
        "title": "Gennex Laboratories Ltd Valuation Turns Very Attractive Amid Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-ltd-valuation-turns-very-attractive-amid-market-pressure-3997830",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GennexLaborator_valuationdot_3997830.png",
        "date": "2026-05-19 08:01:56",
        "description": "Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a significant shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent share price declines and underperformance relative to the Sensex, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present compelling value compared to peers and historical averages."
      }
    ],
    "total": 175,
    "sid": "930938",
    "stock_news_url": "https://www.marketsmojo.com/news/gennex-laboratories-930938"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "01-Jun-2026",
      "details": "Pursuant to Regulation 47 of SEBI (LODR) Regulations 2015 please find enclosed herewith Newspaper publication on Audited (Standalone and Consolidated) Financial Results for the Quarter and year ended March 31 2026 announced by the Board of Directors in its meeting held on May 30 2026. Financial Results had been published in both Business Standard (English) and Saksham (Telugu-Local) on June 01 2026. We request you to take the above information on record and acknowledge receipt of the same.",
      "source": "BSE"
    },
    {
      "caption": "Financial Result For The Quarter And Year Ended March 31 2026",
      "datetime": "30-May-2026",
      "details": "In just concluded Meeting of Board of Directors the Board approved and considered the following items: 1. Audited Standalone & Consolidated Financial Results for the Quarter and Year ended March 31 2026. 2. Auditors Report on audited Standalone and Consolidated Financial Statements for the Quarter and Year ended March 31 2026 issued on dated May 30 2026 along with the Statement on Impact of Audit Qualification (Standalone and Consolidated) are attached herewith. We hereby submit that the Board Meeting had commenced at 4:00 pm and concluded at 7:30 pm. This intimation is also uploaded on the company website www.gennexlab.com",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Meeting Held On Today I.E. 30Th May 2026",
      "datetime": "30-May-2026",
      "details": "In just concluded Meeting of Board of Directors the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the Quarter & Year Ended March 31 2026; 2. Auditors Report on audited Standalone & Consolidated Financial Statements for the Quarter and Year ended March 31 2026 issued on dated May 30 2026 along with the Statement on Impact of Audit Qualification (Standalone & Consolidated) are attached herewith - Annexure I; We hereby submit that the Board Meeting had commenced at 4:00 PM and concluded at 7.30 PM. This intimation is also uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Gennex Laboratories Ltd has announced <strong>1:10</strong> stock split, ex-date: 14 Dec 09",
          "dt": "2009-12-14",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Gennex Laboratories Ltd has announced <strong>1:2</strong> rights issue, ex-date: 21 Jul 22",
          "dt": "2022-07-21",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Gennex Laboratories Ltd is Rated Hold

2026-06-11 10:10:40

Gennex Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Are Gennex Laboratories Ltd latest results good or bad?

2026-06-02 19:35:43

Gennex Laboratories Ltd's latest financial results for the quarter ended March 2026 present a complex picture. The company achieved net sales of ₹60.96 crores, reflecting a substantial year-on-year growth of 51.15%, which marks the highest quarterly revenue in its recent history. This growth indicates robust demand for Gennex's products, particularly in the active pharmaceutical ingredients (API) and intermediates segment. However, this impressive top-line growth was not mirrored in profitability metrics. The operating margin, excluding other income, fell sharply to 9.66% from 23.61% in the same quarter last year, indicating significant margin compression. This decline raises concerns about the company's cost management and pricing strategies, suggesting that the growth may have come at the expense of profitability. The net profit for the quarter was reported at ₹3.74 crores, which, while showing a year-on...

Read full news article

Gennex Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-06-02 08:04:15

Gennex Laboratories Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, driven by a notable decline in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change comes against a backdrop of mixed sector performance and a challenging market environment, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks.

Read full news article

Gennex Laboratories Q4 FY26: Profit Surge Masks Margin Compression Concerns

2026-06-01 15:16:03

Gennex Laboratories Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharmaceutical ingredients and intermediates, reported consolidated net profit of ₹3.74 crores for Q4 FY26, marking a robust 61.21% year-on-year growth but a concerning 28.63% sequential decline. The Telangana-based company, with a market capitalisation of ₹285.00 crores, saw its stock retreat 4.42% to ₹11.25 following the results announcement, reflecting investor concerns over deteriorating operating margins despite impressive top-line expansion.

Read full news article

Gennex Laboratories Ltd Reports Strong Quarterly Turnaround Amid Mixed Long-Term Returns

2026-06-01 12:01:16

Gennex Laboratories Ltd has demonstrated a notable turnaround in its financial performance for the quarter ended March 2026, with significant growth in profitability and revenue, despite a challenging market environment and a recent downgrade in its Mojo Grade to Sell.

Read full news article

Are Gennex Laboratories Ltd latest results good or bad?

2026-05-30 19:51:14

Gennex Laboratories Ltd's latest financial results present a mixed picture, highlighting both robust revenue growth and significant operational challenges. For the fiscal year 2025, the company reported a notable net sales increase of 59.30% year-on-year, reaching ₹137.00 crores, up from ₹86.00 crores in the previous year. This growth is supported by a strong five-year compound annual growth rate (CAGR) of 22.71%, indicating a consistent upward trend in sales. However, the operational metrics reveal concerning trends. The net profit for FY25 rose to ₹18.00 crores, reflecting a 38.46% increase year-on-year, but this growth lagged behind the sales expansion. The profit after tax margin contracted to 13.10% from 15.10% in FY24, suggesting deteriorating operational efficiency. Furthermore, the operating margin (excluding other income) saw a significant decline, dropping to 11.70% from 19.80%, raising questions...

Read full news article

Gennex Laboratories Ltd is Rated Sell

2026-05-29 10:10:03

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Read full news article

When is the next results date for Gennex Laboratories Ltd?

2026-05-20 23:19:00

The next results date for Gennex Laboratories Ltd is scheduled for 30 May 2026....

Read full news article

Gennex Laboratories Ltd Valuation Turns Very Attractive Amid Market Pressure

2026-05-19 08:01:56

Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a significant shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent share price declines and underperformance relative to the Sensex, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present compelling value compared to peers and historical averages.

Read full news article

View All News